Position of the Transparency Council – Keytruda (pembrolizumab)

At its meeting on 8 July 2024, the Transparency Council adopted position No. 64/2024 on the evaluation of the drug Keytruda (pembrolizumab) within the framework of the drug program B.148 “Treatment of patients with endometrial cancer (ICD-10: C54)”

Publication of the position >>